Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer

Future Oncology
Rudolph M Navari

Abstract

Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life. The emetogenicity of the chemotherapeutic agents, repeated chemotherapy cycles and patient characteristics (e.g., female gender, younger age, low alcohol consumption and history of motion sickness) are the major risk factors for CINV. This article provides a detailed description of palonosetron, a second-generation 5-hydroxytryptamine-3 (5-HT(3)) receptor antagonist, which has been approved for the prevention of acute CINV in patients receiving either moderately or highly emetogenic chemotherapy and for the prevention of delayed CINV in patients receiving moderately emetogenic chemotherapy. In recent studies, compared with the first-generation 5-HT(3) receptor antagonists, palonosetron in combination with dexamethasone demonstrated better control of delayed CINV in patients receiving highly emetogenic chemotherapy and had a similar safety profile. Owing to its efficacy in controlling both acute and delayed CINV, palonosetron may be very effective in the clinical setting of multiple-day chemotherapy and bone marrow transplantation.

References

Aug 9, 2003·Blood·Daniela CapelloGianluca Gaidano
Aug 19, 2003·The Annals of Pharmacotherapy·Rudolph M Navari, Jim M Koeller
Feb 5, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P EisenbergA Macciocchi
May 13, 2004·Cancer·Steven M GrunbergGedske Daugaard
Nov 19, 2004·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Fausto RoilaJorn Herrstedt
Dec 16, 2004·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Steven M GrunbergMaurizio Tonato
Feb 9, 2005·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Rudolph M NavariW Pletcher
Feb 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Olga Geling, Hans-Georg Eichler
Mar 1, 2006·Expert Opinion on Emerging Drugs·Rudolph M Navari, Paula S Province
May 24, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·UNKNOWN American Society of Clinical OncologySteven M Grunberg
Nov 15, 2006·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Lorenzo CohenHenry Hu
Jan 24, 2007·Journal of the National Comprehensive Cancer Network : JNCCN·Rudolph M Navari
Mar 22, 2007·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Rudolph M NavariCynthia S Johnson
Apr 17, 2007·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Lawrence H EinhornJoseph Bubalo
Jul 18, 2008·Anesthesia and Analgesia·Camilo RojasBarbara Slusher
Oct 8, 2008·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Maurizio MussoTania Perrone
Feb 20, 2009·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Bart C De Jonghe, Charles C Horn
May 13, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carolyn D SeibBrent T Shoji
Oct 20, 2009·European Journal of Pharmacology·Camilo RojasBarbara S Slusher

❮ Previous
Next ❯

Citations

Jan 15, 2013·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Rudolph M NavariSarah E Gray
Mar 19, 2013·Expert Opinion on Pharmacotherapy·Michelle C JanelsinsGary R Morrow
Apr 4, 2015·Biochimica Et Biophysica Acta·Rudolph M Navari
Oct 1, 2015·BioMed Research International·Rudolph M Navari
May 8, 2013·Expert Opinion on Pharmacotherapy·Rudolph Navari
Oct 18, 2014·Expert Opinion on Pharmacotherapy·Rudolph M Navari
May 1, 2016·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Kaoru KubotaTakashi Ogura
Mar 3, 2020·Medicinal Research Reviews·Radomir JuzaJan Korabecny

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
Rudolph M NavariCynthia S Johnson
Expert Opinion on Drug Metabolism & Toxicology
Kamalesh K SankhalaSant P Chawla
Expert Opinion on Pharmacotherapy
Rudolph M Navari
Expert Opinion on Emerging Drugs
Rudolph M Navari, Paula S Province
© 2021 Meta ULC. All rights reserved